Activation of NLRP2 in Triple-Negative Breast Cancer sensitizes chemotherapeutic therapy through facilitating hnRNPK function
Biochemical Pharmacology · 2023
DOI: 10.1016/j.bcp.2023.115703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Lai Jin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Nanjing Medical University, Nanjing 211116, PR China. Electronic address: ljin@njmu.edu.cn. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National College Students Innovation and Entrepreneurship Training Program, Innovative Research Group Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Nucleotide-binding oligomerization domain (NOD)-like receptor type 2 protein (NLRP2) was reported to inhibit NF-κB in response to inflammatory stimuli, but its role in tumors remains elusive. We screened out NLRP2 from mouse models of breast cancer metastasis. Bioinformatics analysis showed NLRP2 expression was positively correlated with survival rate and negatively correlated with the potential of cancer metastasis. Its significance in Triple-Negative Breast Cancer (TNBC) was investigated by gain- and loss-of-function studies in vivo and vitro. Re-expression of NLRP2 dramatically inhibited the growth and metastasis of the xenograft model of MDA-MB-231 cells. Mechanically, NLRP2 confined hnRNPK within cytoplasm, which in turn blocked vimentin mRNA production. Not only that, NLRP2 further enhanced the H2O2-induced high level of p53&Bax and hence dramatically increased the apoptosis rate (fivefold). Likewise, carboplatin-treated cells showed decreased cell viability, suggesting that patients of TNBC with high level of NLRP2 respond well to chemotherapeutics. Under the stimulus of H2O2, NLRP2-hnRNPK no longer stayed in the cytoplasm, but entered the nucleus to increase the expression of p53 and hence enhanced corresponding apoptosis effect, increasing Bax expression. It suggested that NLRP2 helps p53 enter the nucleus to induce apoptosis. This study revealed a novel function of NLRP2 that modulated oncogenic and anti-oncogenic characteristics of hnRNPK, and provided a new biomarker for TNBC chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Nanjing Medical University, Nanjing 211116, PR China. Electronic address: ljin@njmu.edu.cn.
- Department of Pharmacology, Nanjing Medical University, Nanjing 211116, PR China.
- Department of Pharmacology, Nanjing Medical University, Nanjing 211116, PR China. Electronic address: snli@njmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- National College Students Innovation and Entrepreneurship Training Program
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Jin, L., Li, T., Hong, Y., Mao, R., Li, X., Zhu, C., Mu, J., Zhou, J., Pan, L., Que, Y., Xia, Y., Zhang, Y., & Li, S. (2023). Activation of NLRP2 in Triple-Negative Breast Cancer sensitizes chemotherapeutic therapy through facilitating hnRNPK function. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115703
Vancouver
Jin L, Li T, Hong Y, Mao R, Li X, Zhu C, et al. Activation of NLRP2 in Triple-Negative Breast Cancer sensitizes chemotherapeutic therapy through facilitating hnRNPK function. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115703
BibTeX
@article{Jin2023,
author = {Jin, Lai and Li, Tiantian and Hong, Yali and Mao, Rongchen and Li, Xu and Zhu, Chao and Mu, Junyu and Zhou, Jun and Pan, Lihua and Que, Yuhui and Xia, Yidong and Zhang, Yuheng and Li, Shengnan},
title = {Activation of NLRP2 in Triple-Negative Breast Cancer sensitizes chemotherapeutic therapy through facilitating hnRNPK function},
journal = {Biochemical Pharmacology},
year = {2023},
doi = {10.1016/j.bcp.2023.115703}
}
EUVIMED